Table 2.

Peripheral blood immune cell population according to lenvatinib treatment.

	Cell proportion of total live cells (%)				P valuea	P valueb
	Total	Pre-treatment (4 samples from 4 patients)	On-treatment (23 samples from 10 patients)	Off-treatment (4 samples from 4 patients)
Total lymphocytes	56.5 (14.7)	47.4 (24.3)	57.7 (12.9)	58.9 (15.2)	0.21	0.87
CD8+ T cells	12.3 (6.3)	10.9 (7.0)	12.2 (6.2)	14.3 (7.0)	0.71	0.54
Central memory	0.9 (0.5)	1.2 (0.7)	0.8 (0.5)	0.9 (0.3)	0.29	0.95
Effector memory	1.9 (1.1)	1.4 (1.1)	1.9 (1.1)	2.4 (1.1)	0.47	0.32
Terminal effector	7.5 (5.1)	7.1 (4.6)	7.3 (5.3)	9.6 (5.0)	0.95	0.42
CD4+ T cells	14.9 (7.0)	17.0 (8.8)	14.0 (6.4)	18.2 (9.2)	0.41	0.26
Central memory	7.1 (4.2)	9.7 (4.6)	6.5 (3.8)	8.1 (5.5)	0.13	0.46
Effector memory	1.9 (1.5)	1.8 (2.3)	1.7 (1.3)	3.2 (1.7)	0.86	0.06
Terminal effector	3.0 (1.9)	3.8 (2.3)	2.6 (1.7)	4.5 (2.0)	0.24	0.06
Regulatory T cells	0.2 (0.1)	0.2 (0.2)	0.1 (0.1)	0.2 (0.1)	0.49	0.21
B cells	8.6 (4.5)	8.8 (5.9)	8.1 (4.1)	11.3 (5.4)	0.78	0.18
NK cells	18.3 (8.2)	9.3 (4.5)	20.8 (7.9)	13.3 (3.1)	0.009	0.07
Early	2.8 (1.0)	1.6 (0.3)	3.1 (0.9)	1.9 (0.4)	0.004	0.02
Late	15.6 (7.5)	7.7 (4.6)	17.6 (7.4)	11.4 (2.8)	0.02	0.11
Monocytes	18.3 (8.3)	25.3 (12.5)	16.9 (6.2)	19.4 (13.0)	0.27	0.73
Dendritic cells	0.9 (0.5)	1.1 (0.6)	0.9 (0.5)	1.1 (0.7)	0.34	0.54
LMR	4.0 (2.4)	2.6 (2.2)	4.1 (2.2)	4.7 (3.6)	0.23	0.65

Continuous variables are presented as means (standard deviations).

LMR lymphocyte to monocyte ratio.

^aP values for the comparison between the pre-treatment (4 samples from 4 patients) and on-treatment (23 samples from 10 patients).

^bP values for the comparison between the on-treatment (23 samples from 10 patients) and off-treatment (4 samples from 4 patients).